Court Opinion

ID: 9411074
Source: CourtListenerOpinion
Date Created: 2023-07-25 18:04:44.473541+00
Date Added: 2024-06-11T17:21:02.561470
License: Public Domain

Filed 7/25/23 Edwards-Behar v. Dobry CA4/1

                 NOT TO BE PUBLISHED IN OFFICIAL REPORTS
California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for
publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication
or ordered published for purposes of rule 8.1115.

                COURT OF APPEAL, FOURTH APPELLATE DISTRICT

                                                 DIVISION ONE

                                         STATE OF CALIFORNIA

 TATYANA A. EDWARDS-BEHAR,                                            D080420

           Plaintiff and Appellant,

           v.                                                       (Super. Ct. No.
                                                                     37-2019-00064332-CU-MM-CTL)
 MARY M. DOBRY,

           Defendant and Respondent.

         APPEAL from a judgment of the Superior Court of San Diego County,
Ronald F. Frazier, Judge. Affirmed.
         Bove Law Group and Brook Leone Bove for Plaintiff and Appellant.
         LaFollett, Johnson, DeHaas, Fesler & Ames and James J. Wallace II;
Cole Pedroza and Kenneth R. Pedroza, Nicole F. DeVanon for Defendant and
Respondent.
         Tatyana Edwards-Behar (Edwards) appeals a summary judgment in
favor of respondent Mary Dobry, M.D. on Edwards’s complaint for medical
malpractice based on alleged delay in diagnosing melanoma. We affirm.
                 FACTUAL AND PROCEDURAL HISTORY
      The undisputed facts show that on February 26, 2018, Edwards
consulted with Dr. Dobry concerning a lesion on her right upper arm. Dr.
Dobry’s notes indicated Edwards had multiple lesions. On August 23, 2018,
Edwards returned to Dr. Dobry for a consultation. Dr. Dobry did not perform

a biopsy of Edwards’s lesions on either of those visits.1 During a December
2018 visit, Dr. Dobry noticed a lesion on Edwards’s right arm had changed,
and ordered a biopsy, which confirmed a diagnosis of malignant melanoma.
      A January 2019 nuclear medicine test revealed intense activity with at
least three distinct foci in Edwards’s right axilla. After a further biopsy, one
of Edwards’s lymph nodes tested positive for metastatic melanoma. In
January 2019, Edwards began a year-long immunotherapy treatment. The
following month, an oncologist determined she had stage 3 melanoma that
had metastasized to her lymph node. After six months of treatment, an
ultrasound of Edwards’s right upper arm detected no abnormal lymph nodes.
Edwards’s Complaint
      Edwards sued Dr. Dobry, alleging a single cause of action for medical
malpractice. She claims Dr. Dobry “so negligently and carelessly examined,
diagnosed, cared for, treated and rendered medical services upon the person

1      The parties dispute Edwards’s purpose in making those two 2018 visits
to Dr. Dobry’s office, with Dr. Dobry claiming Edwards sought Botox
treatment in the first visit, and that although Edwards had numerous
lesions, there were no signs of skin cancer. Edwards claims that during both
visits she specifically requested a biopsy of a lesion on her upper right arm.
We examine the evidence independently, and “our account of the facts is
presented in the light most favorable to the nonmoving party below, in this
case [Edwards], and assumes that, for purposes of our analysis, her version of
all disputed facts is the correct one.” (Birschtein v. New United Motor
Manufacturing, Inc. (2001) 92 Cal.App.4th 994, 999; accord, Miller v.
Department of Corrections (2005) 36 Cal.4th 446, 470.)
                                        2
and body of [Edwards] . . . that as a direct and proximate result thereof,
[Edwards] was caused to and did suffer” injuries. Edwards specifically claims
she “was injured in her health, strength and activity, sustaining severe shock
and injury to her nervous system and person, causing her mental, physical
and nervous pain and suffering and resulting in disability all to her damage.”
Dr. Dobry’s Motion for Summary Judgment
      Dr. Dobry moved for summary judgment on grounds her treatment of
Edwards was within the applicable standard of care, and she did not cause
any of Edwards’s injuries. Dr. Dobry submitted two medical experts’
declarations. Adam Rotunda, M.D., a dermatologist, reviewed Dr. Dobry’s
medical records of Edwards and noted Edwards had a history of visits with
Dr. Dobry from as early as 2011. He said that at each visit, Dr. Dobry
indicated Edwards had “numerous precancerous lesions . . . located on her
trunk and extremities, which were treated with liquid nitrogen or curetted.
Of note, on all visits, [Dr. Dobry] specifically noted that [Edwards] did not
have any atypical moles or skin cancer.” Dr. Rotunda stated that during
Edwards’s February 2018 and August 2018 visits, Dr. Dobry observed no skin
cancers. But after the August 2018 visit, Dr. Dobry advised Edwards “to
return in one month for another checkup.” Dr. Rotunda added that in
December 2018, Dr. Dobry noted Edwards had a right arm lesion that was
questionable for cancer. A biopsy performed on that day confirmed
melanoma.
      Dr. Rotunda affirmed: “Edwards had a significant and long history of
sun damage and precancerous lesions examined by and treated by [Dr.
Dobry]. Photographs of [Edwards] reveal significant sun damage on her right
arm.” Dr. Rotunda opined Dr. Dobry’s treatment of Edwards “was at all
times within the standard of care in the community of dermatologists.” He

                                       3
concluded that “Dr. Dobry’s visits with [Edwards] every three to six months
were appropriate.”
      Dr. Rotunda opined: “From the pathology reports, I believe that [ ]
Edwards’s melanoma was very aggressive and based upon the depth,
presence of ulceration and the mitotic rate of the melanoma cells[,] I believe
that the malignant melanoma lesion diagnosed by Dr. Dobry in December of
2018 was not present during an earlier visit with [Edwards] in August of
2018 and was therefore de novo (new)[.] This is the most common
presentation of melanoma. Moreover, it is very feasible given the
aggressiveness of the lesion pathologically, and the fact that the lesion was
only 0.6 [centimeters] on examination (relatively small), that it arose within
the [six] months since her last visit. . . . [¶] Moreover, the pathology report
by the . . . pathologists did not suggest the presence of any scarring, which
would suggest that the biopsy site was previously treated by [Dr. Dobry].”
      Edward McClay, M.D., a defense oncology expert, reviewed Dr. Dobry’s
notes of Edwards’s February 2018 visit and stated, “Multiple actinic

keratosis[2 ] lesions were noted, including one at the right shoulder, eight on
the patient’s back, and four on her arms. The lesion on the right shoulder
was curetted to remove it.” Dr. Dobry’s notes of Edwards’s August 2018 visit
state “there were no atypical moles, and there were no signs of skin cancer.
There was no indications [sic] of lesions suspicious for melanoma. [Edwards]
was advised to return in one month for another checkup. [She] failed to
return in [one] month, in fact delaying her return by [four] months[.] At this
time the lesion on the right [arm] looked markedly different.”

2     Dr. Rotunda in his declaration states “actinic keratosis” are
“precancerous lesions.”
                                       4
      Dr. McClay stated that based on the January 2019 nuclear medicine
test, “There was metastatic melanoma involving one of the six lymph nodes,
however, only [five] malignant cells were identified. Patients with small
metastatic lesions (less than or equal to one [millimeter]) such as this, have a
survival that is equivalent to similar individuals with no metastasis in the
lymph node.”
      Dr. McClay concluded Dr. Dobry’s care and treatment of Edwards “was
not the cause of any injuries alleged by [Edwards].” He stated Edwards had
a rare type of melanoma that is diagnosed in only approximately 5000
patients a year. He added, “[t]his form of [melanoma] has the appearance of
a pimple, typically red in color and frequently does not have the same
characteristics of a pigmented melanoma, which is more common.”
      Dr. McClay opined: “Even if Dr. Dobry had made the melanoma
diagnosis four months earlier, in August of 2018 the prognosis would have
been the same for [Edwards]. . . . [Her] chance of five-year survival is 65 to
70 percent. Even if the lesion was diagnosed in August of 2018, [Edwards’s]
prognosis would not be different, and her five-year chance of survival was
still greater than 50 percent.” Dr. McClay pointed out, “As the CT scans of
[Edwards’s] chest, abdomen, and pelvis were [unremarkable], there is no
evidence of a distant metastases of the melanoma.”
Edwards’s Opposition to Summary Judgment
      In opposing the motion, Edwards argued Dr. Dobry’s treatment of her
fell below the standard of care for dermatologists, and caused her injuries.
Edwards submitted her own declaration in which she stated: “The main
reason I went to Dr. Dobry on February 26, 2018, was to show her a
suspicious lesion on my upper right arm. Suspecting/fearing that it was
cancerous, I requested a biopsy. . . . Dr. Dobry told me the suspicious lesion

                                       5
on my upper right arm looked fine—that it looked like a standard keratosis.
Dr. Dobry reassured me that it was ‘nothing to worry about’ and declined to
perform a biopsy. Instead, Dr. Dobry curetted and applied liquid nitrogen to
the lesion.” Edwards stated Dr. Dobry likewise rejected her August 2018
request for a biopsy, but finally performed one in December 2018, when her
cancer was diagnosed.
      Edwards also submitted declarations of three medical experts. Deede
Liu, M.D., a dermatologist, reviewed Edwards’s medical records and opined
Dr. Dobry should have biopsied Edwards’s lesion in February 2018, and the
delay in doing so caused the cancer to progress from stage 1 or 2 to stage 3.
According to Dr. Liu, the December 2018 biopsy results “demonstrated that
the melanoma had a class IIb molecular signature. This finding is associated
with of risk of [sic] recurrence within [five] years of 54 [percent.]” Dr. Liu
opined that Dr. Dobry’s failure to biopsy the lesion on that date breached the
standard of care.
      Richard Buckley, M.D., another dermatology expert, reviewed
Edwards’s medical records. He opined “Dr. Dobry’s negligence in not
performing the biopsy on [February 26, 2018,] was a substantial factor in
causing harm to [Edwards, who] to a medical certainty would have been
[s]tage 1 or 2 if the biopsy had been performed [then] with a [five]-year
survival rate of 98 [percent] and now is a [s]tage 3 with a [five]-year survival
rate of 63 [percent].”
      John Fruehauf, M.D., Edwards’s oncology expert, reviewed Edwards’s
medical records and stated the December 2018 biopsy demonstrated
Edwards’s melanoma’s molecular signature “is associated with a risk of
recurrence within [five] years of 54 [percent].” Based on a medical journal
article, he concluded that if Dr. Dobry had performed the biopsy in February

                                        6
2018, Edwards’s 10-year survival rate would have been 88 percent. However,
as Edwards was diagnosed with stage 3C melanoma in January 2019, her 10-
year survival rate dropped to 60 percent. Dr. Fruehauf stated Edwards’s
“most recent scans from January 13, 2021[,] and May 11, 2021[,] were clear of
recurrence.” Dr. Fruehauf opined that Dr. Dobry’s “negligence was a
substantial factor in causing harm to [Edwards]. A 10[-]month delay in
biopsy of the lesion was significant in terms of tumor progression. If the
lesion had been biopsied on [February 26, 2018,] the tumor more likely than
not would have been curable and probably a stage 2 or 3.”
Dr. Dobry’s Reply
      Dr. Dobry in reply objected to the declarations by Edwards’s experts,
who relied on Edwards’s own declaration, which was not included in the
medical records. Dr. Dobry argued Edwards’s “experts fail[ed] to identify any
specific information contained in the medical records upon which they base
their opinions evidencing the disputed fact that [Edwards’s] melanoma

existed in February or August 2018.”3
The Court’s Ruling
      Following an unreported hearing, the court granted Dr. Dobry’s motion
for summary judgment based on Edwards’s “inability to prove causation on a
‘lost chance’ theory as outlined in the case of Dumas v. Cooney (1991) 235
Cal.App.3d 1593. [(Dumas)].” The court noted triable issues of fact exist
regarding the separate question of whether Dr. Dobry met the standard of
care, as shown by the parties’ opposing expert declarations; nevertheless, it
did not base its ruling on that ground.

3     The court did not rule on Dr. Dobry’s evidentiary objections.

                                          7
                                 DISCUSSION
      Edwards contends: “As to the question of causation, [she] raised a
material issue of fact . . . , namely that if [Dr. Dobry] had sent the curetted
sample to pathology for testing in February 2018, [Edwards’s] cancer would
have been discovered at an earlier stage than stage 3. . . . The survival rate
for stage 2 is approximately 88 [percent] and drops to 60 [percent] for stage
3.” She adds that the “trial court’s reliance on Dumas[, supra, 235
Cal.App.3d 1593] is misplaced and the court should have looked at traditional
proximate cause.” Finally, in arguing the grant of summary judgment was
erroneous, Edwards points to differences in the opposing experts’ analysis of
her melanoma: “The expert evidence that the delay in diagnosis caused
ulceration and spreading to the lymph nodes is admissible and should be
considered by a jury. The trial court did not rule it inadmissible in any way.
Any dispute in that evidence only strengthens the argument that a jury
should be allowed to weigh the expert opinions and make a decision as to the
facts.”
                             I. Standard of Review
      We review an order granting summary judgment de novo. (Gonzalez v.
Mathis (2021) 12 Cal.5th 29, 39.) “ ‘In practical effect, we assume the role of
a trial court and apply the same rules and standards which govern a trial
court’s determination of a motion for summary judgment.’ ” (Shugart v.
Regents of University of California (2011) 199 Cal.App.4th 499, 504-505;
Hernandez v. KWPH Enterprises (2004) 116 Cal.App.4th 170, 175 [“The
appellate court ‘must assume the role of the trial court and redetermine the
merits of the motion’ using the same standards required below”].)
      A defendant seeking summary judgment bears “the burden of
persuasion” that one or more elements of the cause of action in question

                                        8
cannot be established or that there is a complete defense to it. (Aguilar v.
Atlantic Richfield Co. (2001) 25 Cal.4th 826, 850.) The defendant also “bears
an initial burden of production to make a prima facie showing” that no triable
issue of material fact exists; if he carries his burden of production, “he causes
a shift, and the opposing party is then subjected to a burden of production of
his own to make a prima facie showing of the existence of a triable issue of
material fact.” (Ibid.; Code Civ. Proc., § 437c, subds. (o), (p)(2).)
        II. Law on Medical Malpractice and the “Lost Chance” Theory
      “ ‘The elements of a cause of action in tort for professional negligence
are: (1) the duty of the professional to use such skill, prudence and diligence
as other members of his profession commonly possess and exercise; (2) a
breach of that duty; (3) a proximate causal connection between the negligent
conduct and the resulting injury; and (4) actual loss or damage resulting from
the professional’s negligence.’ ” (Burgess v. Superior Court (1992) 2 Cal.4th
1064, 1077.)
      “As a general rule, the testimony of an expert witness is required in
every professional negligence case to establish . . . whether any negligence by
the defendant caused the plaintiff’s damages.” (Scott v. Rayhrer (2010) 185
Cal.App.4th 1535, 1542.) Dumas involved a medical malpractice action
arising from delayed diagnosis and treatment of lung cancer. There the
plaintiff claimed he was entitled to damages for the lost chance of a possible
cure, possible lengthening of life or possible improved physical comfort even if
the evidence showed less than a probability that the defendant caused such
loss. (Dumas, supra, 235 Cal.App.3d at pp. 1607-1610.)
      The Dumas court addressed “the theory of lost chance, a theory
heretofore unrecognized in California that permits recovery even though the

                                         9
evidence shows no more than a better-than-even chance that a defendant
caused a plaintiff’s loss.” (Dumas, supra, 235 Cal.App.3d at pp. 1600-1601.)
The court elaborated: “Liability for medical malpractice is predicated upon a
proximate causal connection between the negligent conduct and the resulting
injury. [Citation.] ‘[C]ausation must be proven within a reasonable medical
probability based upon competent expert testimony. Mere possibility alone is
insufficient to establish a prima facie case. [Citations.] That there is a
distinction between a reasonable medical ‘probability’ and a medical
‘possibility’ needs little discussion. There can be many possible ‘causes,’
indeed, an infinite number of circumstances which can produce an injury or
disease. A possible cause only becomes ‘probable’ when, in the absence of
other reasonable causal explanations, it becomes more likely than not that
the injury was a result of its action. This is the outer limit of inference upon
which an issue may be submitted to the jury.’ ” (Dumas, supra, at p. 1603.)
      The Dumas court declined “to establish a more lenient standard of
causation in medical malpractice cases to account for the theory of lost
chance.” (Dumas, supra, 235 Cal.App.3d at p. 1608.) Instead, it held the
traditional rule of causation applies in delayed diagnosis cases, such that the
evidence must establish a probability of a better result absent negligence.
(Id. at p. 1603.)
      The Dumas court observed that the lost chance theory “is, in reality,
focused on causation rather than injury and damages. [¶] A lost chance of
survival or a better result cannot be proven unless and until the death or
adversity occurs. Otherwise, in the case of a loss proven by statistics alone, a
court could be placed in a position of awarding damages without injury, e.g.,
in the case of a patient who ‘miraculously recovers despite the negligence and
unfavorable odds.’ [Citation.] The true injury in lost chance cases is

                                       10
therefore the death or adversity. [Citation.] Thus, ‘when we strip away the
rhetoric, damages are really being awarded for the possibility that the
negligence was a cause of the death.’ [Citation.] Stated another way, ‘[t]he
recognition of a lost chance as a cognizable injury is necessarily based on the
reasoning that but for the defendant’s negligence, the plaintiff might possibly
have avoided an adverse result. Thus, recognition of lost chance as a
recoverable interest contradicts the very notion of cause in fact.’ ” (Dumas,
supra, 235 Cal.App.3d at pp. 1609-1610.)
                                  III. Analysis
      Edwards claims “the trial court’s reliance on Dumas was prejudicial
error because the ‘lost chance’ theory of causation is inapplicable where she
can and did assert a theory of traditional proximate cause.” (Some
capitalization and emphasis omitted.) But Edwards in effect relies on the
lost cause theory of causation because, based on the declaration of her expert,
Dr. Fruehauf, she argues the issue here is that if Dr. Dobry had detected her
cancer earlier, she would have benefitted from the higher survival rate for
stage 2 cancer, which is approximately 88 percent; instead, her survival rate
dropped to 60 percent as a stage 3 cancer patient.
      On this summary judgment record, the only injury Dr. Dobry’s delayed
diagnosis arguably caused is the increased chance that Edwards will not
survive for five years (and in the case of Dr. Fruehauf’s declaration, which we
credit,10 years). Under Dumas, in order to proceed to trial there must be
evidence that it is more likely than not Edwards will not survive for those
time periods as a result of the delayed diagnosis. However, despite the fact
the experts disagreed slightly on the precise 5-year survival rate, it is
undisputed that Edwards’s chance of survival for those periods exceeds 50
percent regardless of whether the cancer was diagnosed in February 2018 or

                                       11
December 2018. Accordingly, Edwards has not shown within a reasonable
medical probability that the delay caused her injury. She cannot recover
merely for the decrease in her survival rate. This is because California courts
have consistently rejected recovery for a lost chance of survival “ ‘where the
evidence indicates that there is less than a probability, i.e., a 50-50 possibility
or a mere chance,’ that the injury would have ensued.” (Duarte v. Zachariah
(1994) 22 Cal.App.4th 1652, 1657-1660, quoting Dumas, supra, 235
Cal.App.3d at pp. 1603-1611; see also Bromme v. Pavitt (1992) 5 Cal.App.4th
1487, 1505-1506 [“Dumas recognized there are countervailing policy
arguments which dictate against extending liability to situations where it is
not medically probable the physician’s negligence caused the harm alleged”];
Simmons v. West Covina Medical Clinic (1989) 212 Cal.App.3d 696, 706
[“Under the facts of this case, we decline to establish a more lenient standard
of causation. To do so would be contrary to sound logic, legal precedent, and
public policy”].)
      Even interpreting Edwards’s evidence liberally as we must (Gonzalez v.
Mathis, supra, 12 Cal.5th at p. 39), Edwards has not shown there was a
probability (versus a mere possibility) of a better result absent any negligence
on Dr. Dobry’s part. Accordingly, her claim fails under the traditional rule of
causation (Dumas, supra, at pp. 1603-1611), and the court did not err in
granting summary judgment in Dr. Dobry’s favor.

                                        12
                             DISPOSITION
     The judgment is affirmed. Respondent is awarded her costs on appeal.

                                                           O’ROURKE, J.

WE CONCUR:

HUFFMAN, Acting P. J.

DO, J.

                                   13